Actively Recruiting
Real-World Study of Satralizumab Treatment in Chinese Patients with Neuromyelitis Optica Spectrum Disorder
Led by Huashan Hospital · Updated on 2026-09-18
100
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the clinical outcomes of Chinese patients with Neuromyelitis Optica Spectrum Disorder NMOSD who are treated with satralizumab, a monoclonal antibody approved in China for this condition. This observational study aims to collect real-world follow-up data to understand how patients respond to satralizumab under routine clinical care, addressing the need for optimized patient management given the treatments home administration advantage. Participants in this study are those diagnosed with NMOSD who have tested positive for the AQP4 antibody and who have experienced relapses within the past one to two years. They are receiving or expected to receive satralizumab treatment for at least 12 months. The study gathers data on treatment outcomes without intervening, focusing on the natural course and management of satralizumab therapy in clinical practice. Throughout the study, participants clinical status is monitored at various time points up to 12 months, including relapse rates and changes in disability measured by the EDSS score. Additional assessments include clinical outcome patterns and recording any adverse events during treatment. The study spans from baseline through 12 months of treatment, collecting data to assess the proportion of patients who remain relapse-free and changes in neurological function.
CONDITIONS
Brief Title
HANDLE-a Real World Study on Satralizumab in NMOSD
Research Team
C
Chao Quan, Doctor
W
Wenjuan Huang, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here